All In Biotech

Drug Trial Radar · NCT06388083

A Phase 2/3 Study to Evaluate the Efficacy and Safety of Tinlarebant in Subjects With Stargardt Disease

A Phase 1b Open-label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Tinlarebant in Japanese Subjects With Stargardt Disease and a Phase 2/3 Randomized, Double-masked, and Placebo-controlled Study to Evaluate the Safety, Tolerability, and Efficacy of Tinlarebant in Subjects With Stargardt Disease

Last checked: Nov 19, 2026Latest source record: Mar 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

60

Planned (sponsor's estimate)

Start

Jul 31, 2024

Primary completion

Feb 2028

Study completion Feb 2028

Sponsor

Lead sponsor
Belite Bio, IncIndustry
Sponsor type
Industry
First posted
Apr 29, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to evaluate the safety, tolerability, and efficacy of tinlarebant in subjects with Stargardt Disease

Conditions

  • STGD1
  • Stargardt Disease 1

Interventions

  • TinlarebantDrug

    5 mg tablet

  • PlaceboDrug

    Placebo tablets

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To measure the annualized rate of change from baseline lesion size in aggregate area of atrophyTime frame: From baseline to Month 24

Locations

18 sites in 3 countries. Site status is shown where the registry gives one.

  • Belite Study Site - US08

    Phoenix, Arizona

  • Belite Study Site - US05

    La Jolla, California

  • Belite Study Site - US09

    San Francisco, California

  • Belite Study Site - US06

    Miami, Florida

  • Belite Study Site - US01

    Boston, Massachusetts

  • Belite Study Site - US11

    Edina, Minnesota

  • Belite Study Site - US04

    Rochester, Minnesota

  • Belite Study Site - US14

    New York, New York

  • Belite Study Site - US10

    Westbury, New York

  • Belite Study Site - US02

    Durham, North Carolina

  • Belite Study Site - US07

    Philadelphia, Pennsylvania

  • Belite Study Site - US13

    Austin, Texas

  • Belite Study Site - US03

    Dallas, Texas

  • Belite Study Site - US12

    The Woodlands, Texas

  • Belite Study Site

    Kobe, Japan

  • Belite Study Site

    Kyoto, Japan

  • Belite Study Site

    Tokyo, Japan

  • UK01 Belite Study Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.